Chi3L1 is a therapeutic target in bone metabolism and a potential clinical marker in patients with osteoporosis

Kyung Ran Park, Jae Il Park, Seongsoo Lee, Kyeongwon Yoo, Gi Ryang Kweon, Il Keun Kwon, Hyung Mun Yun, Jin Tae Hong

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

BMP2 is clinically used as an ectopic bone inducer and plays a significant role in bone development, formation, and diseases. Chitinase 3-like 1 protein (Chi3L1) is found in the skeletal system. However, Chi3L1-mediated bone metabolism and aging-related bone erosion via BMP2 signaling have not yet been demonstrated. Herein, Chi3L1 increased BMP2-induced osteoblast differentiation in mesenchymal precursor cells and human primary osteoblasts. Chi3L1KO(-/-) showed abnormal bone development, and primary osteoblasts isolated from Chi3L1KO(-/-) exhibited impaired osteoblast differentiation and maturation. Chi3L1 also potentiated BMP2 signaling and RUNX2 expression in primary osteoblasts. Chi3L1 interacted with BMPRIa, which increased the surface expression of BMPRIa and promoted BMP2 signaling to induce osteoblast differentiation. Chi3L1KO(-/-) mice showed bone formation reduced with a decrease in RUNX2 expression in calvarial defects. Chi3L1KO(-/-) mice exhibited aging-related osteoporotic bone loss with decreases in the levels of RUNX2 and OPG, while serum PYD level and osteoclast number increased. Chi3L1 increased OPG via non-canonical BMP2 signaling in osteoblasts, which suppressed osteoclastogenesis in BMMs. Furthermore, ROC analysis showed that serum Chi3L1 level clinically decreased in osteoporosis patients. Our findings demonstrate that Chi3L1 promotes bone formation, suppresses osteoclastogenesis, and prevents aging-related osteoporosis.

Original languageEnglish
Article number106423
JournalPharmacological Research
Volume184
DOIs
Publication statusPublished - Oct 2022

Keywords

  • BMP2
  • BMPRIa
  • Bone metabolism
  • Chi3L1
  • Osteoporosis

Fingerprint

Dive into the research topics of 'Chi3L1 is a therapeutic target in bone metabolism and a potential clinical marker in patients with osteoporosis'. Together they form a unique fingerprint.

Cite this